Lifeloc Technologies, Inc

LCTC
About the company

Lifeloc Technologies, Inc. develops, manufactures, and markets portable hand-held and fixed station breathalyzers and related accessories for law enforcement, workplace, corrections, original equipment manufacturing, and consumer markets internationally. It offers fuel-cell-based breath alcohol testing equipment; and a line of supplies, accessories, services, and training to support customers' alcohol testing programs. The company also develops and sells online drug and alcohol training and refresher courses.

Country: United StatesPrice: $3.50Market Cap: $9.6M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

1 / 15

NEUTRAL / FAIL

Median fair value

$1.58

-54.9% vs price

Models with upside

0 / 17

Positive margin of safety

Strongest signal

7 of 12 pass — Buffett, Lynch, Piotroski +2 more object

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2146 (Top 69.3%)FAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/A-121.5%N/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-27

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-27

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Qualitative assessment

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-27

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage58% pass✓ 10✗ 5▾

    7 of 12 pass — Buffett, Lynch, Piotroski +2 more object

    LT Debt vs Net Current AssetsLT Debt $1.0M vs NCA $3.7M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.29, IC: -5.8x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.29
    ✓Lynch< 0.33
    Cash - Long-term Debt$-0.1M
    ✗LynchPositive preferred
    LT Debt / Total Assets Change12.83% -> 15.83%
    ✗PiotroskiDecreased YoY
    Current Assets / Current Liabilities4.35
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.29
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.29
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-5.8x, D/EBITDA=N/A
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.29
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.2948; #1978/4210 (top 47.0%)
    ✗AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Profitability0% pass✓ 3✗ 32▾

    No clean pass — all 16 investors flag at least one profitability criterion

    Positive EPS (10 years)12/17 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)-267.3%
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)12/17 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-14.2%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-13.6% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-2.5M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)18.27
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-54.3%
    ✗Lynch> 15%
    EBIT / Enterprise Value-8.1%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-8.1%, ROC=-15.9%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-36.95%
    ✗PiotroskiROA > 0
    ROA Change YoY-12.07% -> -36.95% (delta: -24.88%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-7.47%, ROA=-36.95%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY40.4% -> 40.3%
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-54.3%
    ✗Dreman> 12%
    Margin of SafetyP/B=2.3x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-24.6% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency12/16 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-8.7%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-54.3%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-2.0% (2023) -> -13.6% (2025)
    ✗TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 43.3% -> 40.3%, operating margin -2.0% -> -13.6%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-21.50%; #4606/6340 (top 72.6%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+54.93%; #558/3702 (top 15.1%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity-54.26%; #4260/5226 (top 81.5%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.1554; #3973/5884 (top 67.5%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR-2.3% over 5 years
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years6/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Valuation0% pass✓ 1✗ 27▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio2.3x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-8.1%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-8.1%, ROC=-15.9%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share2.3x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-25.8%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-10.0%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=2.3x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low189% of trailing low ($1.85)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-21.50%; #4606/6340 (top 72.6%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.3962; #3298/6449 (top 51.1%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share2.39x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-38.0%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.9621; #1811/5247 (top 34.5%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-8.49%; #3173/4519 (top 70.2%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+79.49%; #432/6202 (top 7.0%)
    ✓OshaughnessyTop 10% of eligible cross-section
  • Verdicts0% pass✗ 16▾

    Split decision: 15 FAIL · 1 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (2/7)✗GreenblattRank #2146✗PiotroskiFAIL (F-Score 2)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (2/5)✗AckmanFAIL (3/9)✗TempletonFAIL (2/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1630/2370 (Top 68.8%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Cash Flow10% pass✓ 2✗ 10▾

    9 of 10 flag LCTC's cash flow — Buffett, Lynch, Piotroski +6 more

    Free Cash Flow Proxy$-2.5M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-1.0M
    ✗LynchPositive and growing
    Operating Cash Flow$-0.5M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-7.47%, ROA=-36.95%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-10.0%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive9/16 years FCF positive
    ✓MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-8.5%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency11/16 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-0.8M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-8.49%; #3173/4519 (top 70.2%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth13% pass✓ 4✗ 9▾

    7 of 8 flag LCTC's growth — Graham, Lynch, Dreman +4 more

    EPS Growth (3-yr avg, 10-yr window)-267.3%
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: -5.0% vs Rev: 9.1%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$0.17 (2010) -> $-0.90 (2025)
    ✗DremanPositive over recent years
    EPS CAGR-5.6% CAGR over 13 years
    ✗Dreman> 5% annualized
    Positive Net Income Frequency12/16 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth5.7%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency2/5 years with positive EPS growth
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 43.3% -> 40.3%, operating margin -2.0% -> -13.6%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR7.3%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR-2.3% over 5 years
    ✗Neff7%-20% annualized
  • Efficiency25% pass✓ 3✗ 8▾

    6 of 8 flag LCTC's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio4.35
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-11.3%
    ✗Buffett> 10%
    ROIC - WACC-21.3%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-15.9%
    ✗Greenblatt> 25%
    Current Ratio Change YoY6.85 -> 5.10
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.98x -> 1.35x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities4.35
    ✓Dreman> 1.5
    Return on Invested Capital-12.8%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-2.0%; FY2024: ROIC=-15.0%; FY2025: ROIC=-18.6%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest -18.6%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Measuring and Control Equipment
SIC Sector: Measuring & Medical Instruments
Size: Micro Cap($9.6M)
Revenue: $9.0M+5.7% YoY
Net Income: $2.5M-134.6% YoY

Financial Snapshot

Operating Margin-13.6%
Return on Equity-60.2%
Debt / Equity0.27
Current Ratio5.10
EPS (Diluted)$-0.90
Shares Retired−3.3% / −12.2% 2y

Similar Companies

TMOTHERMO FISHER SCIENTIFIC INC.
$259.4B
DHRDANAHER CORP /DE/
$163.9B
WATWATERS CORP /DE/
$90.5B
AAGILENT TECHNOLOGIES, INC.
$49.0B

Shareholder Return

Fiscal 2025

Issued 3.3% of shares last year, 12.2% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, interest expense, operating cash flow, depreciation amortization, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-03-27
FY 2024
Sources
  • 10-K · 2025-03-28
FY 2023
Sources
  • 10-K · 2024-04-01
FY 2022
Sources
  • 10-K · 2023-03-14
FY 2021
Sources
  • 10-K · 2022-03-03
Market Cap$9.6Mcurrent------$7.8Mest.$9.0Mest.$4.7Mest.$4.7Mest.$11.7Mest.
Revenue$9.5M↑10%$2.5M↑12%$2.4M↑10%$2.3M↑1%$9.0M↑6%$8.5M↓8%$9.3M↑10%$8.5M↑20%$7.1M
Operating Income-$618.5K↑53%-$50.1K↑79%-$103.6K↑73%-$128.0K↑54%-$1.2M↑13%-$1.4M↓637%-$191.1K↑71%-$650.3K↓142%-$268.9K
Net Income-$1.9M↓50%-$84.9K↑68%-$134.3K↑66%-$152.7K↑48%-$2.5M↓135%-$1.1M↓612%$205.6K↑145%-$455.8K↓167%$676.0K
EPS (Diluted)--$-0.03↑70%$-0.05↑64%$-0.06↑45%$-0.90↓120%$-0.41↓613%$0.08↑142%$-0.19↓170%$0.27
Gross Margin42.7%↑7%43.2%↑8%44.7%↑7%43.0%↑8%40.3%40.4%↓7%43.3%↑19%36.3%↓16%43.4%
Operating Margin-6.5%↑57%-2.0%↑81%-4.2%↑75%-5.6%↑55%-13.6%↑17%-16.5%↓705%-2.0%↑73%-7.7%↓101%-3.8%
ROE-50.7%↓126%———-60.2%↓256%-16.9%↓623%3.2%↑144%-7.4%↓172%10.3%
Total Debt$1.1M↓5%$1.1M↓5%$1.1M↓1%$1.1M↓5%$1.1M↓5%$1.2M↓4%$1.2M↓4%$1.3M↓4%$1.3M
Shareholders' Equity$3.7M↓34%$3.7M↓34%$3.8M↓35%$4.0M↓37%$4.1M↓34%$6.2M↓2%$6.4M↑3%$6.2M↓7%$6.6M
Current Ratio3.95↓22%3.95↓22%4.35↓16%4.11↓18%5.10↓26%6.85↑38%4.97↓4%5.17↓4%5.41
Debt / Equity0.29↑43%0.29↑43%0.29↑52%0.28↑52%0.27↑44%0.19↓2%0.19↓7%0.21↑3%0.20
Operating Cash Flow$64.5K↑107%$248.0K↑231%-$133.2K↑54%-$129.4K↓29%-$499.3K↑62%-$1.3M↓153%-$525.7K↓1068%$54.3K↓70%$182.9K
Free Cash Flow-$364.2K$248.0K↑221%-$133.2K-$134.7K-$962.1K↑48%-$1.9M↓251%-$532.6K↓235%-$158.9K↓92%-$82.9K

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Measuring and Control Equipment

LCTC vs Peers — Financial Grading

Revenue$9.0MBottom 25%
Net Income$2.5MBottom 25%
ROE-60.2%Bottom 25%
D/E0.27Top 25%
Op. Margin-13.6%Bottom 25%
Curr. Ratio5.10Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
THERMO FISHER SCIENTIFIC INC.TMO$259.4B$700.22$44.6B$6.7B12.6%0.7417.4%1.893/93/93/71/3F-Score 57/11
DANAHER CORP /DE/DHR$163.9B$233.02$24.6B$3.6B6.9%0.3519.1%1.873/94/92/71/3F-Score 54/11
WATERS CORP /DE/WAT$90.5B$460.25$3.2B$642.6M25.1%0.5525.4%1.731/94/91/70/3F-Score 45/11
AGILENT TECHNOLOGIES, INC.A$49.0B$173.96$6.9B$1.3B19.3%0.4521.3%1.962/95/93/71/3F-Score 55/11
ROPER TECHNOLOGIES INCROP$47.5B$479.98$7.9B$1.5B7.7%0.4728.3%0.522/93/93/70/3F-Score 64/11
COHERENT CORP.COHR$43.0B$218.15$5.8B$49.4M0.9%0.691.6%2.193/91/90/70/3F-Score 44/11
TERADYNE, INCTER$39.0B$249.55$3.2B$554.0M19.8%0.0720.4%1.752/96/94/71/3F-Score 66/11
ILLUMINA, INC.ILMN$31.3B$207.01$4.3B$850.0M31.2%0.7318.6%2.082/91/93/71/3F-Score 85/11